To elucidate whether PD-L1 expression reflects host-tumor immunity, we evaluated CD8+ TILs, since the presence of particular TIL subsets correlates with better prognosis in cutaneous melanoma, colorectal cancer, esophageal cancer, renal cancer, and ovarian cancer [15–21]. This evidence concerns the gene CD8A and ovarian carcinoma.